

Clinical Edit Criteria Proposal

Drug/Drug Class: STIMULANTS

Prepared for:
Prepared by: Missouri Medicaid

☐ New Criteria

☒ Revision of Existing Criteria

Executive Summary

Purpose: To continue to monitor and control pharmacy program prescription cost by applying clinical edits to the CNS stimulant medication class.

Why was this Issue Selected: Since 1992 the stimulants have required prior authorization. To assist providers with claims processing and to reduce program costs, this therapeutic class will no longer require PA, but will be processed with clinical edits.

Program-specific information: During the twelve-month reporting period of July 2002 to June 2003 (FY 2003), 106,031 claims were paid for stimulant therapy at a cost of 7.6 million dollars. This represents approximately 0.8% of the total prescription drug benefit spend over the same calendar period.

Setting & Population: All patients prescribed stimulants.

Type of Criteria:

<input type="checkbox"/> Increased risk of ADE	<input type="checkbox"/> Non-Preferred Agent
<input checked="" type="checkbox"/> Appropriate Indications	<input checked="" type="checkbox"/> Appropriate Utilization

Data Sources:

<input checked="" type="checkbox"/> Only administrative databases	<input type="checkbox"/> Databases + Prescriber-supplied
---	--

Purpose of Clinical Edit Criteria

Under the Omnibus Budget Reconciliation Act of 1993, Congress clinical edit is used to control utilization of products that have very narrow indications or high abuse potential. While prescription expenditures are increasing at double-digit rates, payors are also evaluating ways to control these costs by influencing prescriber behavior and guide appropriate medication usage. Clinical edit criteria assist in the achievement of qualitative and economic goals related to health care resource utilization. Restricting the use of certain medications can reduce costs by requiring documentation of appropriate indications for use, and where appropriate, encourage the use of less expensive agents within a drug class. Clinical edit criteria can also reduce the risk for adverse events associated with medications by identifying patients at increased risk due to diseases or medical conditions, or those in need of dosing modifications.

Setting & Population

- Drug class for review: Stimulants
- Age range: All patients
- Gender: Male & female

Approval Criteria

- Therapy can be approved for the following indications:

Condition	Submitted ICD-9 Diagnoses	Inferred Diagnosis	History Date Range
Attention Deficit Disorder without hyperactivity	314.00	----	730 days
Attention Deficit Disorder with hyperactivity	314.01	----	730 days
Narcolepsy	347	Subject to clinical review	730 days

- Under 18 years old - appropriate diagnosis
- 18 years of age to 23 years of age
 - Appropriate diagnosis
 - Current academic/work enrollment
- Over 23 years childhood onset (before 12 years of age) with history of treatment
 - Current academic/work enrollment
 - Care supervised by mental health specialist



Denial Criteria

- Inappropriate Diagnosis

Required Documentation

Laboratory results:
MedWatch form:

☐
☐

Progress notes:
Other: Appropriate Diagnosis

☐
☒

Disposition of Edit

- **Denial:** Exception 682 "Clinical Edit"

References

1. USPDI, Micromedex, 2003.
2. Facts and Comparisons, p.770-775.
3. EBM Analysis: Stimulants. Cassica Schlichtmann, Pharm.D. Candidate, Drake University. February 2003.

Revised 11/2003

